{"name":"AbbVie (prior sponsor, Abbott)","slug":"abbvie-prior-sponsor-abbott","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"infectious","drugs":[{"name":"ABT-288 Low Dose","genericName":"ABT-288 Low Dose","slug":"abt-288-low-dose","indication":"Other","status":"phase_2"},{"name":"ABT-348","genericName":"ABT-348","slug":"abt-348","indication":"Other","status":"phase_1"},{"name":"ABT-348 and carboplatin","genericName":"ABT-348 and carboplatin","slug":"abt-348-and-carboplatin","indication":"Other","status":"phase_1"},{"name":"ABT-652 NSAID","genericName":"ABT-652 NSAID","slug":"abt-652-nsaid","indication":"Other","status":"phase_2"},{"name":"ABT-700","genericName":"ABT-700","slug":"abt-700","indication":"Other","status":"phase_1"},{"name":"ABT-767","genericName":"ABT-767","slug":"abt-767","indication":"Other","status":"phase_1"},{"name":"ABT-806","genericName":"ABT-806","slug":"abt-806","indication":"Other","status":"phase_2"},{"name":"ABT-981","genericName":"ABT-981","slug":"abt-981","indication":"Other","status":"phase_2"},{"name":"Placebo (PBO) oral capsules","genericName":"Placebo (PBO) oral capsules","slug":"placebo-pbo-oral-capsules","indication":"Control arm in phase 3 clinical trials (non-therapeutic use)","status":"phase_3"},{"name":"Placebo for ABT-333","genericName":"Placebo for ABT-333","slug":"placebo-for-abt-333","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"ABT-333","genericName":"ABT-333","slug":"abt-333","indication":"Chronic hepatitis C virus infection (genotype 1)","status":"phase_3"},{"name":"ABT-267","genericName":"ABT-267","slug":"abt-267","indication":"Diabetic kidney disease","status":"phase_3"},{"name":"ABT-450","genericName":"ABT-450","slug":"abt-450","indication":"Chronic hepatitis C virus (HCV) infection","status":"phase_2"},{"name":"ABT-450/r/ABT-267, ABT-333","genericName":"ABT-450/r/ABT-267, ABT-333","slug":"abt-450-r-abt-267-abt-333","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1","status":"phase_3"},{"name":"ABT-450/ritonavir","genericName":"ABT-450/ritonavir","slug":"abt-450-ritonavir","indication":"Chronic hepatitis C virus infection (genotype 1 and 4)","status":"phase_3"},{"name":"Placebo for ABT-450/r/ABT-267","genericName":"Placebo for ABT-450/r/ABT-267","slug":"placebo-for-abt-450-r-abt-267","indication":"Hepatitis C virus infection (control arm in phase 3 trials)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"respiratory","drugs":[{"name":"ABT-348 and azacitidine","genericName":"ABT-348 and azacitidine","slug":"abt-348-and-azacitidine","indication":"Acute myeloid leukemia","status":"phase_1"},{"name":"ABT-348 and docetaxel","genericName":"ABT-348 and docetaxel","slug":"abt-348-and-docetaxel","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"ABT-712","genericName":"ABT-712","slug":"abt-712","indication":"Lung cancer with FGFR1 alterations","status":"phase_3"},{"name":"ABT-888","genericName":"ABT-888","slug":"abt-888","indication":"Metastatic breast cancer, triple-negative breast cancer, ovarian cancer","status":"phase_2"},{"name":"Leuprolide Acetate 3 Month Depot","genericName":"Leuprolide Acetate 3 Month Depot","slug":"leuprolide-acetate-3-month-depot","indication":"Advanced prostate cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"rare","drugs":[{"name":"Adalimumab, current formulation","genericName":"Adalimumab, current formulation","slug":"adalimumab-current-formulation","indication":"Rheumatoid Arthritis","status":"phase_2"},{"name":"Adalimumab, new formulation","genericName":"Adalimumab, new formulation","slug":"adalimumab-new-formulation","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"Open-label Adalimumab","genericName":"Open-label Adalimumab","slug":"open-label-adalimumab","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"Atrasentan high dose group","genericName":"Atrasentan high dose group","slug":"atrasentan-high-dose-group","indication":"Hypertension","status":"phase_2"},{"name":"Atrasentan low dose group","genericName":"Atrasentan low dose group","slug":"atrasentan-low-dose-group","indication":"Pulmonary arterial hypertension","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ABT-652","genericName":"ABT-652","slug":"abt-652","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ABT-894","genericName":"ABT-894","slug":"abt-894","indication":"Relapsing multiple sclerosis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ABT-288 High Dose","genericName":"ABT-288 High Dose","slug":"abt-288-high-dose","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ABT-333","genericName":"ABT-333","slug":"abt-333","phase":"phase_3","mechanism":"ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1)"],"catalyst":""},{"name":"ABT-652","genericName":"ABT-652","slug":"abt-652","phase":"phase_2","mechanism":"ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"ABT-894","genericName":"ABT-894","slug":"abt-894","phase":"phase_2","mechanism":"ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Relapsing multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"ABT-267","genericName":"ABT-267","slug":"abt-267","phase":"phase_3","mechanism":"ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation.","indications":["Diabetic kidney disease","Liver fibrosis / NASH (non-alcoholic steatohepatitis)"],"catalyst":""},{"name":"ABT-288 High Dose","genericName":"ABT-288 High Dose","slug":"abt-288-high-dose","phase":"phase_2","mechanism":"ABT-288 High Dose is a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ABT-288 Low Dose","genericName":"ABT-288 Low Dose","slug":"abt-288-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-348","genericName":"ABT-348","slug":"abt-348","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-348 and azacitidine","genericName":"ABT-348 and azacitidine","slug":"abt-348-and-azacitidine","phase":"phase_1","mechanism":"AZA is a hypomethylating agent that targets DNA methyltransferase enzymes.","indications":["Acute myeloid leukemia","Myelodysplastic syndromes"],"catalyst":""},{"name":"ABT-348 and carboplatin","genericName":"ABT-348 and carboplatin","slug":"abt-348-and-carboplatin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-348 and docetaxel","genericName":"ABT-348 and docetaxel","slug":"abt-348-and-docetaxel","phase":"phase_1","mechanism":"Docetaxel is a microtubule inhibitor that works by stabilizing microtubules and preventing cell division.","indications":["Non-small cell lung cancer","Breast cancer","Prostate cancer"],"catalyst":""},{"name":"ABT-450","genericName":"ABT-450","slug":"abt-450","phase":"phase_2","mechanism":"ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus.","indications":["Chronic hepatitis C virus (HCV) infection","HCV genotype 1 infection"],"catalyst":""},{"name":"ABT-450/r/ABT-267, ABT-333","genericName":"ABT-450/r/ABT-267, ABT-333","slug":"abt-450-r-abt-267-abt-333","phase":"phase_3","mechanism":"This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1"],"catalyst":""},{"name":"ABT-450/ritonavir","genericName":"ABT-450/ritonavir","slug":"abt-450-ritonavir","phase":"phase_3","mechanism":"ABT-450 is a hepatitis C virus NS3/4A protease inhibitor that blocks viral replication, boosted by ritonavir to increase drug levels.","indications":["Chronic hepatitis C virus infection (genotype 1 and 4)"],"catalyst":""},{"name":"ABT-652 NSAID","genericName":"ABT-652 NSAID","slug":"abt-652-nsaid","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-700","genericName":"ABT-700","slug":"abt-700","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-712","genericName":"ABT-712","slug":"abt-712","phase":"phase_3","mechanism":"ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation.","indications":["Lung cancer with FGFR1 alterations","Other solid tumors with FGFR1 dependency"],"catalyst":""},{"name":"ABT-767","genericName":"ABT-767","slug":"abt-767","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-806","genericName":"ABT-806","slug":"abt-806","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-888","genericName":"ABT-888","slug":"abt-888","phase":"phase_2","mechanism":"ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.","indications":["Metastatic breast cancer, triple-negative breast cancer, ovarian cancer"],"catalyst":""},{"name":"ABT-981","genericName":"ABT-981","slug":"abt-981","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adalimumab, current formulation","genericName":"Adalimumab, current formulation","slug":"adalimumab-current-formulation","phase":"phase_2","mechanism":"Tumor necrosis factor-alpha inhibitor","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Crohn's Disease","Ulcerative Colitis"],"catalyst":""},{"name":"Adalimumab, new formulation","genericName":"Adalimumab, new formulation","slug":"adalimumab-new-formulation","phase":"phase_2","mechanism":"Adalimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Atrasentan high dose group","genericName":"Atrasentan high dose group","slug":"atrasentan-high-dose-group","phase":"phase_2","mechanism":"Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.","indications":["Hypertension"],"catalyst":""},{"name":"Atrasentan low dose group","genericName":"Atrasentan low dose group","slug":"atrasentan-low-dose-group","phase":"phase_2","mechanism":"Endothelin receptor antagonist","indications":["Pulmonary arterial hypertension"],"catalyst":""},{"name":"Leuprolide Acetate 3 Month Depot","genericName":"Leuprolide Acetate 3 Month Depot","slug":"leuprolide-acetate-3-month-depot","phase":"phase_3","mechanism":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids (leiomyomata)","Central precocious puberty"],"catalyst":""},{"name":"Open-label Adalimumab","genericName":"Open-label Adalimumab","slug":"open-label-adalimumab","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Placebo (PBO) oral capsules","genericName":"Placebo (PBO) oral capsules","slug":"placebo-pbo-oral-capsules","phase":"phase_3","mechanism":"Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit.","indications":["Control arm in phase 3 clinical trials (non-therapeutic use)"],"catalyst":""},{"name":"Placebo for ABT-333","genericName":"Placebo for ABT-333","slug":"placebo-for-abt-333","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":[],"catalyst":""},{"name":"Placebo for ABT-450/r/ABT-267","genericName":"Placebo for ABT-450/r/ABT-267","slug":"placebo-for-abt-450-r-abt-267","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":["Hepatitis C virus infection (control arm in phase 3 trials)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOOUFLbjJKUmtyUEdLV0s4U090bUlKR2s1cDg3Wk1QcDE5NldTY1Q0OWItTjd4NC12WDdPMnFWbTRydFNHRGx4NlM2dFhTN0UwUGd2bGg0OGNBR2pMamFzbXllQkhoMjM2NnUtN3NxYjVucUFPc09YeGoweW5Zbm11c3VlSGdjNlE?oc=5","date":"2026-02-12","type":"pipeline","source":"AOL.com","summary":"Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever - AOL.com","headline":"Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOZnZrcnEzdW91WllRSzlfbUFQdjdVVkxiSW14cG1PaDVhOWRlclJSZ2t6WWUxWVV6RENPcEdwMGU2dW1weU1mM0NuWVFjX3l0bzdkRVc0elZVdEdIUHVSZDRXNl9abzZOalJIY0hxYTRYUDNFNjRkUm5PbWwzYU1weG5SUW90U2JBeGM1cQ?oc=5","date":"2025-02-28","type":"pipeline","source":"SEC.gov","summary":"abbv-20241231 - SEC.gov","headline":"abbv-20241231","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1CdmZUQmczSF8tX3ZGRnJlUzhqeTg1NUowdjRrNTVXQ1A3MVdPeXBocUcwd0pmLXBwakZtNDg3cDhETk9yTGRYUnA4N1podFhaSEhr?oc=5","date":"2024-11-03","type":"pipeline","source":"Site Selection Magazine","summary":"Singapore Spin - Site Selection Magazine","headline":"Singapore Spin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQZ01LVlFjWk8wOFpPcEQ3cm5abVhEbmVfMkRyV2RqS3YwYlV3WldweGUxOV9DMUZoaEwzVWo0eW1KY0dWOThSX0NWMERrSEkyM3o0NTZLUlhPdVUyUHFrcFVDS05HaDlMNzI1TElaZ0ViX0VoeWhZeFNpekIyU2xvWUVrSWc?oc=5","date":"2024-09-16","type":"pipeline","source":"HR Executive","summary":"Creating culture from the ground-up: How AbbVie did it - HR Executive","headline":"Creating culture from the ground-up: How AbbVie did it","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxONTdvdzR1WTFQbUxad2FEc202clU1Um1hbUYzOHV5LVJ6R3FPdnFSWHhLcGZMUTlieUZOWDQxa21JSXctMFFtdk1IdjY1V0xpSjlqUXpNSHJIaHJMekpueFdhbk9zMS10RXQwck05Vk5iT1RoTlhzZGE2WTlmWWkwZG16T2FTdEJ0czczUkRpLU1vTy1EaHhFVnQ0WlJXMVRXSDBYRnBNMnNxM29OUzQ3YVBZRkxoOGdEb1VmcHZCdTBVNmUySlp0VzcwY2d5NUs5alk2dzYwQXQ?oc=5","date":"2024-03-07","type":"pipeline","source":"Disney Advertising Press","summary":"The Biggest Brands Flock to the 96th Oscars® Disney Advertising Sells Out of Ad Inventory for the Telecast - Disney Advertising Press","headline":"The Biggest Brands Flock to the 96th Oscars® Disney Advertising Sells Out of Ad Inventory for the Telecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNeEdSVzFRLUZkQVk3bzdoT01mYVFVanZwdUhuRnZncnhIWjQxUUwyOGhubVRQTkhLUnM1ajhjOWUtZWVaemFibFNkLTFVQ0kxNTgwOXV6Q2NGX3c3NXdLcm9Nc3FjSE4xWXI2U29JZG9VOTlCWkd5QXdTWi02cnYwNEtyemJvUQ?oc=5","date":"2024-03-07","type":"pipeline","source":"ADWEEK","summary":"Disney Sells Out Ad Inventory for 96th Oscars With Pricing Back Up - ADWEEK","headline":"Disney Sells Out Ad Inventory for 96th Oscars With Pricing Back Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQT0hFcUQ4Y25pZzY2bDhySXlpOFNyZjZHMGo0c1pYT1llRTdIRFVIU3V3Rzdjby05MG1xV2JzY2J3ejVqX00zdVJoZDVfQXJla19kQ0RjdUw5eGFmT3U5WnBpTTV1NVBLZ2JReGFMTWNzYXI1a2VzWGJsVWlkTmFLQ05EcHBBUGNST3MzU1JFNUVyOGJl?oc=5","date":"2024-02-20","type":"pipeline","source":"BioPharma Dive","summary":"Rick Gonzalez, longtime AbbVie CEO, to step down in July - BioPharma Dive","headline":"Rick Gonzalez, longtime AbbVie CEO, to step down in July","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPT2ttYnlaS3ZMVVFhNW5vVnFlWDlDVTc2MlplV0Z2M19QdWszYVdweWpHZVFlMHAzWnVqRWVobFh5UnZDRWZCSWJ6OTRSWFdnbUJFTWRaY2FrLV9RcGRvNG4xVGtkejhOZHBFNHNET0ZBTVBEeE1BRDVIcWUweDBSQnlrRWdxUWFTelB0bg?oc=5","date":"2024-02-20","type":"pipeline","source":"pharmaphorum","summary":"AbbVie looks internally for its new CEO, naming COO Michael - pharmaphorum","headline":"AbbVie looks internally for its new CEO, naming COO Michael","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNb1RCV0ZWWWtyMGdZMjcxNlV1UGwwcEk4YzQ5RXItRWQ2VlRZWlhkc1VNdjZhU3lTQmFtTGsycVg5OWk3Mm9zNE1XY1VUWW5KQWc4dVhZNTlHWU5ZQXZkU3Axd0E1bzdhWEwyNzF4Q2FPdW5CWGplN0VGNnNZbUEyZA?oc=5","date":"2022-10-19","type":"pipeline","source":"| Governance Intelligence","summary":"AbbVie legal chief to retire - | Governance Intelligence","headline":"AbbVie legal chief to retire - | Governance Intelligence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNZG84NjQ3aElhVEo5aVVsdnN2VkJGWFRnMXVQRXd3QllyVW1VdTI3U19PWkdxRGVNMFRzRldTWDN6VVZyalpBVDFoWjFkRWxUZ0d2ZmJaV3NrdlJ2eWhpTTlqbm42S21yN05fRDZGMldLaTdMZFM0ODVNZHJZUklBWkRIQ2otY3k2WEpfdEIzTE5pZw?oc=5","date":"2022-03-17","type":"pipeline","source":"BioPharma Dive","summary":"Two decades and $200 billion: AbbVie’s Humira monopoly nears its end - BioPharma Dive","headline":"Two decades and $200 billion: AbbVie’s Humira monopoly nears its end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPU3NXVXVCNGlxZ201TGhaeTJBa2VLc09wR3cwRUg4eE00MGFSY0hpaG13T0FnSzZwMXJJWXBMcUZrRFFPTjZ4algzZFN0dnZGbkNPNHBOZ2dEYm85TWFidzdsYUEwZDlPVEhQTFk2M21XSW5YQ09QNjJ4Z3lIZXotMEhKaThDUUlkT25qNmVfcThYaXpSMFZIUFBOMTg5c3RRbWo5cGpsZmpRV01XN0FkQjVkSWFiZ2h4ZHV6ZzRWbHdjMkJKTmdrOXJ5MG9aZmF4ellQRkRPZXRybjFVTXc?oc=5","date":"2017-06-09","type":"trial","source":"Reuters","summary":"AbbVie must pay $15 million in Depakote birth-defect trial: jury - Reuters","headline":"AbbVie must pay $15 million in Depakote birth-defect trial: jury","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBuV0FUN1N3U0hIUVE3NTg0eXF0Vy0wU0RwN1ZsR1JhdmNTRXNUWnU0ckcyb2VqXzgxRHV4Y040TkNUeU1TdUJUQmFqUnVfbW5DaEZrZ2YwQVhaeExqVC1fclZWR0hqVkROeTdSVHRCcTEyRWhMVko3UmZxN0NmTVE?oc=5","date":"2013-10-28","type":"pipeline","source":"pharmaphorum","summary":"A history of Abbott and AbbVie - pharmaphorum","headline":"A history of Abbott and AbbVie","sentiment":"neutral"}],"patents":[],"drugCount":29,"phaseCounts":{"phase_3":10,"phase_2":13,"phase_1":6},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}